Clinical trials: Metastatic Neoplasm
Prostate Cancer
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
The purpose of this study is see if quality of life is improved in patients receiving oral hormone therapy compared to standard of care.
- Trial name
- NCT01342367
- Testing
- Bicalutamide, Dutasteride, Finasteride
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Chicago
Node; Prostate, Bone Metastases
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
As in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive…
- Conditions
- Node; Prostate, Bone Metastases, Prostate Cancer Patients
- Trial name
- POSTCARD (NCT03795207)
- Testing
- SBRT + Durvalumab, SBRT
- Where
- 9 sites in France
- Volunteers
- 96 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly diagnosed metastatic prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01120236
- Testing
- Bicalutamide, Cixutumumab, Goserelin Acetate
- Where
- 170 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
This is a single arm, open phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and refractory colorectal cancer.
- Trial name
- NCT05143099
- Testing
- TEC
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer, Hormone Receptor Positive Tumor
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer
Breast cancer is rarely curable after metastasis, and the therapeutic options are limited. Interestingly, the host immune response is strongly predictive for the effect of chemotherapy in subgroups of patients with breast cancer.
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor, Metastatic Breast Cancer
- Trial name
- ICON (NCT03409198)
- Testing
- Ipilimumab, Nivolumab, Pegylated liposomal doxorubicin
- Where
- 6 sites in Belgium, Norway
- Volunteers
- 82 people
- Sponsor
- Oslo University Hospital
Breast Cancer, Peripheral Neuropathy
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
- Trial name
- NCT04675450
- Testing
- NBP Softgel Capsules
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Neoplasm
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
The purpose of this study is to determine the highest dose of Liposome Entrapped Paclitaxel Easy to Use formulation (LEP-ETU) that can be safely administered by an intravenous infusion to patients with advanced cancer.
- Trial name
- NCT00080418
- Testing
- Liposome Entrapped Paclitaxel Easy to Use
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Metastatic Prostate Cancer
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
This research study is looking into plasma tumour deoxyribonucleic acid (ptDNA), a substance that is shed by cancer cells and can be detected in blood samples.
- Trial name
- PARADIGM (NCT04067713)
- Where
- 16 sites in United Kingdom
- Volunteers
- 192 people
- Sponsor
- University College, London
Sarcoma, Melanoma
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Background: A tumor cell vaccine is an experimental cancer treatment. Cancer cells are collected from a patient and then used to develop a vaccine.
- Conditions
- Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
- Trial name
- NCT01341496
- Testing
- Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer.
- Conditions
- Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
- Trial name
- NCT02474368
- Testing
- Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroendocrine Tumors
Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors
This is an investigator-initiated research project aimed at exploring the efficacy and safety of Adebrelimab combined with chemotherapy and Apatinib as first-line treatment for unresectable locally advanced or metastatic…
- Trial name
- NCT06764368
- Testing
- Adebrelimab + Apatinib
- Volunteers
- 39 people
- Sponsor
- Beijing Chest Hospital
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Soft Tissue Sarcoma, Metastatic Lung Disease
Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease
The purpose of this study is to evaluate the role of palliative surgery in improving Quality of Life (QoL) and symptom control for patients who present with a Soft Tissue Sarcoma (STS) and metastatic lung disease.
- Trial name
- NCT02080897
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Metastatic Colorectal Cancer
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM.
- Trial name
- NCT06208397
- Testing
- Magnetic Resonance Elastography and routine MRI
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Colorectal Cancer Metastatic
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic…
- Trial name
- METIMMOX (NCT03388190)
- Testing
- Nivolumab, FLOX
- Where
- 5 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Kidney Cancer
Talabostat in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well talabostat works in treating patients with metastatic kidney…
- Trial name
- NCT00489710
- Testing
- talabostat mesylate, enzyme inhibitor therapy, flow cytometry
- Sponsor
- University of Nebraska
Alopecia; X-Rays
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain
Study will be conducted on patients receiving Whole brain(WB) / Partial Brain(PB) radiotherapy using volumetric modulated arc therapy or intensity modulated radiotherapy at Department of Radiation Oncology, Fortis Memorial…
- Trial name
- NCT03543020
- Testing
- radiation therapy to brain
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Fortis Memorial Research Institute
Breast Cancer
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed…
- Trial name
- NCT00087620
- Testing
- XELODA [capecitabine]
- Where
- 35 sites in United States
- Sponsor
- Hoffmann-La Roche
Breast Cancer Stage IV
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.
- Trial name
- 2019-101826 (NCT04896320)
- Testing
- Tucatinib
- Where
- 4 sites in United States
- Sponsor
- Providence Health & Services
Thyroid Neoplasms
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine
- Trial name
- NCT00984282
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 81 sites in United States, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.